Zvonimir Krajcer

Zvonimir Krajcer

Auto-generated profile, based on publicly available information

Zvonimir Krajcer

Department of Cardiology Texas Heart Institute Houston Texas USA

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 March 2007 in Catheterization and Cardiovascular Interventions
Verified
Journal Article
Closed access
PDF file
GYGeorge A. Younis
George A. Younis
KGKamal Gupta
Kamal Gupta
AMAli Mortazavi
Ali Mortazavi
NSNeil E. Strickman
Neil E. Strickman
ZKZvonimir Krajcer
Zvonimir Krajcer
AAArup Achari
Arup Achari

1 December 2002 in Journal of Endovascular Therapy
Verified
Journal Article
Closed access
MHMarcus Howell
Marcus Howell
ZKZvonimir Krajcer
Zvonimir Krajcer
KDKathy Dougherty
Kathy Dougherty
NSNeil Strickman
Neil Strickman
MSMark Skolkin
Mark Skolkin
DPDavid Paniagua
David Paniagua
Purpose: To examine retrospectively the magnitude of change in systolic blood pressure (SBP) during carotid artery stenting and its relationship to neurological events. Methods: In a 5-year period ending October 2000, 60 patients (36 men; mean age 67 ± 9 years) were enrolled in a study to evaluate stenting in symptomatic or asymptomatic high-risk patients with ≥70% carotid artery stenosis. The majority (48, 80%) of the patients were symptomatic. Five patients with bilateral lesions were treated in staged procedures. Sixteen (25%) of the 65 lesions were postsurgical stenoses and 12 (18%) were secondary to neck radiation therapy. Results: There were 2 (3%) minor and 2 (3%) major strokes (94% procedural success), of which 1 was fatal. Six (9%) transient neurological events were recorded during balloon inflation. The mean SBP change during or after stenting in 55 cases without neurological events was 34 ± 14 mmHg, while the patients with transient or permanent neurological events had significantly greater changes in SBP (107 ± 31 mmHg [p<0.003] and 134 ± 14 mmHg [p<0.001], respectively). Patients exhibiting neurological sequelae had significantly higher SBP before the procedure than those without complications (203 ± 30 versus 165 ± 23 mmHg, p<0.001). There were no neurological events in patients with a <50-mmHg change in SBP. Conclusions: Patients with severely elevated baseline SBP (>180 mmHg) may be at higher risk for hemodynamic instability and neurological events during carotid stenting. The greater the change in SBP, the more severe the neurological event seems to be, but further studies in a greater number of patients are needed to evaluate the potential causes of SBP fluctuations in an effort to avoid neurological events.

1 April 2009 in Journal of Endovascular Therapy
Verified
Journal Article
Closed access
PDF file
GIGary M. Idelchik
Gary M. Idelchik
KDKathryn G. Dougherty
Kathryn G. Dougherty
EHEduardo Hernandez
Eduardo Hernandez
AMAli Mortazavi
Ali Mortazavi
NSNeil E. Strickman
Neil E. Strickman
ZKZvonimir Krajcer
Zvonimir Krajcer
Purpose: To determine the safety and efficacy of percutaneous treatment for popliteal artery aneurysms (PAA) using self-expanding stent-grafts. Methods: From October 2000 through September 2007, 29 patients (27 men; mean age 68±6 years, range 54–88) underwent endovascular exclusion of 33 PAAs. All had symptoms of claudication, and all were atherosclerotic in origin. Four patients presented with popliteal venous thrombosis. Twenty-eight of the treated PAAs had associated mural thrombus. The mean aneurysm diameter was 34.3± 13.3 mm and the mean lesion length was 98.6±102.1 mm. Results: All PAAs were successfully excluded from the arterial circulation using 59 stent-grafts (15 Wallgraft and 44 Viabahn). The average number of stent-grafts implanted was 1.9±0.4 (range 1–3); the mean length of covered vessel (per lesion) was 198.6±105.3 mm. There were no device-associated complications or deaths. Over an average follow-up of 35.4±32.1 months (range 6–120), the primary and secondary patency rates, respectively, were 93.9% and 100% at 6 months, 93.9% and 96.9% at 1 year, and 87.5% and 96.8% at 2 years. At 4.5 years, primary and secondary patency rates were 84.8% and 96.8%, respectively. No endoleaks, aneurysm rupture, thromboembolism, or limb loss occurred at follow-up. Conclusion: Stent-graft exclusion of PAAs is safe and effective, yielding primary and secondary patency rates comparable to surgical repair. In spite of encouraging results in this study, further larger studies are warranted to reconfirm our observations.

18 December 2017 in Journal of Endovascular Therapy
Verified
Journal Article
Closed access
ZKZvonimir Krajcer
Zvonimir Krajcer
VRVenkatesh G. Ramaiah
Venkatesh G. Ramaiah
EHEsteban A. Henao
Esteban A. Henao
DMD. Chris Metzger
D. Chris Metzger
WNWayne K. Nelson
Wayne K. Nelson
LMLarry E. Miller
Larry E. Miller
Purpose: To determine the feasibility, perioperative resource utilization, and safety of a fast-track endovascular aneurysm repair (EVAR) protocol in well-selected patients. Methods: Between October 2014 and May 2016, the LIFE (Least Invasive Fast-track EVAR) registry (ClinicalTrials.gov identifier NCT02224794) enrolled 250 patients (mean age 73±8 years; 208 men) in a fast-track EVAR protocol comprised of bilateral percutaneous access using the 14-F Ovation stent-graft, no general anesthesia, no intensive care unit (ICU) admission, and next-day discharge. The primary endpoint was major adverse events (MAE) through 30 days. The target performance goal for the MAE endpoint was 10.4%. Results: Vascular access, stent-graft delivery, and stent-graft deployment success were 100%. A total of 216 (86%) patients completed all elements of the fast-track EVAR protocol. Completion of individual elements was 98% for general anesthesia avoidance, 97% for bilateral percutaneous access, 96% for ICU avoidance, and 92% for next-day discharge. Perioperative outcomes included mean procedure time of 88 minutes, median blood loss of 50 mL, early oral nutrition (median 6 hours), early mobilization (median 8 hours), and short hospitalization (median 26 hours). Fast-track EVAR completers had shorter procedure time (p<0.001), less blood loss (p=0.04), faster return to oral nutrition (p<0.001) and ambulation (p<0.01), and shorter hospital stay (p<0.001). With 241 (96%) of the 250 patients returning for the 30-day follow-up, the MAE incidence was 0.4% (90% CI 0.1% to 1.8%), significantly less than the 10.4% performance goal (p<0.001). No aneurysm rupture, conversion to surgery, or aneurysm-related secondary procedure was reported. There were no type III endoleaks and 1 (0.4%) type I endoleak. Iliac limb occlusion was identified in 2 (0.8%) patients. The 30-day hospital readmission rate was 1.6% overall. Conclusion: A fast-track EVAR protocol was feasible in well-selected patients and resulted in efficient perioperative resource utilization with excellent safety and effectiveness.

20 March 2020 in Journal of Endovascular Therapy
Verified
Journal Article
Closed access
PDF file
ZKZvonimir Krajcer
Zvonimir Krajcer
DWDavid A. Wood
David A. Wood
NSNeil Strickman
Neil Strickman
NBNelson Bernardo
Nelson Bernardo
CMChris Metzger
Chris Metzger
SNSamuel Nardone
Samuel Nardone
Purpose: To evaluate the safety and effectiveness of the MANTA percutaneous vascular closure device in patients undergoing percutaneous endovascular aneurysm repair (PEVAR) or thoracic endovascular aortic repair (TEVAR). Materials and Methods: The SAFE MANTA Study (ClinicalTrials.gov identifier NCT02908880) was a prospective, single-arm, multicenter trial in patients undergoing endovascular interventions using large-bore sheaths (transcatheter aortic valve replacement, PEVAR, or TEVAR) at 20 sites in North America. Patient selection intended to test the MANTA device in populations without morbid obesity, severe calcification, or a severely scarred femoral access area. Of the 263 patients enrolled in the primary analysis cohort, 53 (20.2%) patients (mean age 74.9±8.9 years; 41 men) underwent PEVAR (n=51) or TEVAR (n=2) procedures and form the cohort for this subgroup analysis. Per protocol a single MANTA device was deployed in all PEVAR/TEVAR cases. Results: The mean time to hemostasis in the PEVAR/TEVAR cohort was 35±91 seconds, with a median time of 19 seconds vs 24 seconds in the overall SAFE MANTA population. The MANTA device met the definition for technical success in 52 (98%) of 53 PEVAR/TEVAR cases compared with 97.7% in the overall SAFE MANTA population. One (1.9%) major complication (access-site stenosis) occurred in this subgroup compared to 14 (5.3%) events in the SAFE population. In the PEVAR/TEVAR group, 1 pseudoaneurysm was noted prior to discharge, another at 30-day follow-up, and one at 60 days. One (1.9%) of the 3 minor pseudoaneurysms was treated with ultrasound-guided compression and the other 2 required no treatment. Conclusion: The MANTA device demonstrated a short time to hemostasis and low complication rates compared with published literature results of other percutaneous closure devices. Time to hemostasis and complication rates were comparable between the PEVAR/TEVAR patients and the full SAFE MANTA study cohort. The MANTA device provides reliable closure with a single percutaneous device for PEVAR/TEVAR procedures.

15 April 2004 in Catheterization and Cardiovascular Interventions
Verified
Journal Article
Closed access
PDF file
KGKamal Gupta
Kamal Gupta
KDKathy Dougherty
Kathy Dougherty
HHHeinz Hermman
Heinz Hermman
ZKZvonimir Krajcer
Zvonimir Krajcer